Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2024 | KEYNOTE-716: long-term efficacy and safety of pembrolizumab in resected melanoma

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on updated results from the Phase III KEYNOTE-716 trial (NCT03553836) of adjuvant pembrolizumab in patients with resected stage IIB/IIC melanoma. Pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to placebo, with a median follow-up of four years. A promising recurrence-free survival 2 (PRFS2) was additionally reported. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.